Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.